加德納氏症治療市場－全球產業規模、佔有率、趨勢、機會及預測（按癌症類型、治療藥物類型、最終用戶、地區和競爭格局分類，2021-2031年）

全球加德納氏症治療市場預計將從 2025 年的 203.1 億美元成長到 2031 年的 275.5 億美元，複合年成長率達到 5.21%。

針對這種遺傳性疾病的治療策略包括切除術等外科手術，以及非類固醇消炎劑(NSAIDs) 和 COX-2 抑制劑等藥物治療，以控制多發性息肉和結腸外表現。市場成長的主要驅動力是先進基因篩檢技術的日益普及，這些技術能夠實現早期診斷，以及臨床上對預防性護理（防止良性息肉惡性轉化）的日益關注。

然而，終身監測和複雜手術帶來的巨大經濟負擔仍然是市場廣泛接受該療法的一大障礙。美國癌症協會的報告顯示，預計到2024年，美國將有約152,810人被診斷出患有結直腸癌，這凸顯了腸道病變和遺傳風險管理方面的迫切需求。如此高的發病率表明，即使經濟障礙仍然阻礙著市場的進一步擴張，有效的治療方案仍然至關重要。

市場促進因素

基因篩檢和次世代定序技術的進步，使得精準檢測大腸腺瘤性息肉病基因突變成為可能，並成為市場成長的主要驅動力。這些診斷工具使臨床醫生能夠在腸外症狀或癌症出現之前製定監測通訊協定，以便及時進行手術或藥物干預。腸道疾病在全球日益成長的影響，進一步凸顯了對這類早期檢測系統的需求。區分遺傳性和散發性病例需要強大的檢測能力。根據世界衛生組織（世衛組織）2024年2月發布《全球癌症負擔》的新聞稿，大腸直腸癌是全球第三大常見癌症，2022年估計新增病例達190萬例。

同時，對罕見疾病和疑難雜症藥物研發投入的增加正在擴大市場。在有利於罕見疾病藥物研發的監管環境下，製藥公司獲得了更大的獎勵，這些法規環境提供市場獨佔權和稅收優惠，從而推動了研發重點從單純的外科手術治療轉向藥物預防。根據美國食品藥物管理局（FDA）於2024年1月發布的《2023年新藥核准報告》，2023年核准的55種新療法中有28種被指定用於治療罕見疾病，這標誌著製藥業正持續轉向滿足遺傳性疾病領域未被滿足的醫療需求。此外，死亡率數據也印證了開發這些治療方法的迫切性。根據美國癌症協會（ACS）的預測，到2024年，美國大腸癌死亡人數預計將達到53,010人，這將導致對更有效藥物的需求不斷成長，以提高患者的存活率。

市場挑戰

加納症候群治療領域發展的一大障礙是終身後續觀察和複雜手術帶來的沉重經濟負擔。患有這種遺傳性疾病的患者需要持續的醫療管理，包括頻繁的內視鏡檢查和諸如切除術等大規模的干涉措施，以降低癌症風險，這導致高昂的直接醫療費用限制了患者獲得標準治療的機會。由於無力承受必要的預防性治療方案，患者對治療通訊協定的遵從性較差，導致手術量減少，對藥物治療的需求也隨之降低。

根據美國癌症協會癌症控制網路（ACS CAN）2024年的報告，約47%的患者和倖存者表示難以支付癌症相關費用，包括篩檢和治療費用。這種普遍存在的經濟負擔表明，很大一部分潛在患者可能由於經濟壓力而推遲或放棄重要的後續觀察和手術。因此，由於經濟限制阻礙了必要治療方法的廣泛普及，市場面臨商機。

市場趨勢

受臨床對降低手術創傷和在預防性腸切除術中保護神經功能的需求驅動，微創機器人輔助切除術正成為該領域的一大趨勢。機器人系統越來越受到青睞，尤其是在髂骨儲袋肛管吻合術等重組手術中，因為在狹窄的骨盆腔內進行精準操作對於減少併發症至關重要。這項技術的融合正在迅速重新定義遺傳性大腸直腸疾病的手術標準。根據Intuitive公司於2025年1月發布的“2024年第四季及全年初步財務業績報告”，2024年全球達文西手術量將同比成長約17%，這反映出機器人技術在複雜腹部手術中的應用日益廣泛。

同時，γ-分泌酶抑制劑的引入標誌著纖維瘤（一種危及生命的加德納氏症結腸外表現）治療領域的變革性進展。這一趨勢代表著治療方法的轉變，從高風險、易復發的手術切除轉向標靶藥物抑制Notch訊號通路，進而誘導腫瘤消退。這些新型療法的強勁商業性應用凸顯了對有效非手術治療方案的迫切需求。根據SpringWorks Therapeutics於2025年2月發布的“2024年第四季度及全年財務業績報告”，該公司2024年全年OGSIVEO（nirogacestat）在美國的淨產品銷售額為1.72億美元，表明已通過核准的全身性療法在以往服務不足的患者群體中獲得了顯著的市場認可。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球加德納氏症治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 癌症類型（擴大性心肌病、骨骼肌肉病變、嗜中性白血球低下症、其他）
  • 依治療方法（非類固醇消炎劑（NSAIDs）、COX-2抑制劑）
  • 按最終使用者（醫院/診所、門診護理中心、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美加德納氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲加德納氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區加德納症候群治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲加德納氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲加德納氏症治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球加德納氏症治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Biochem Pharmaceuticals Industries Limited
• Zydus Lifesciences Limited
• Vernalis（R&D）Limited
• Sun Pharmaceutical Industries Ltd.
• Sanofi SA
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Medimetriks Pharmaceuticals, Inc
• Johnson & Johnson Services, Inc.
• Akorn Operating Company LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Gardner Syndrome Treatment Market is projected to expand from USD 20.31 Billion in 2025 to USD 27.55 Billion by 2031, achieving a compound annual growth rate (CAGR) of 5.21%. Treatment strategies for this hereditary condition encompass surgical procedures, such as colectomy, alongside pharmacological therapies like NSAIDs and COX-2 inhibitors intended to control polyposis and extracolonic symptoms. The market is largely propelled by the increasing application of sophisticated genetic screening technologies that enable early diagnosis, combined with a growing clinical focus on prophylactic care designed to stop benign polyps from advancing into malignancies.

Nevertheless, the significant economic costs associated with lifelong monitoring and intricate surgeries pose a major obstacle to broad market accessibility. As reported by the American Cancer Society, approximately 152,810 individuals in the United States are expected to be diagnosed with colorectal cancer in 2024, a figure that emphasizes the substantial need for managing bowel pathologies and genetic risks. This high prevalence highlights the critical necessity for effective therapeutic solutions, even as financial barriers continue to hinder wider market expansion.

Market Driver

The advancement of genetic screening and Next-Generation Sequencing technologies acts as a primary engine for market growth by allowing for the precise detection of Adenomatous Polyposis Coli gene mutations. These diagnostic tools enable clinicians to establish surveillance protocols before the appearance of extracolonic manifestations or cancer, thereby facilitating prompt surgical or pharmacological action. The necessity for such early detection systems is heightened by the rising global impact of bowel pathologies, which requires robust testing frameworks to distinguish hereditary cases from sporadic ones; according to the World Health Organization's 'Global Cancer Burden' press release from February 2024, colorectal cancer was the third most common cancer globally, with an estimated 1.9 million new cases in 2022.

Simultaneously, the market is growing due to increased investment in research and development for orphan drugs and rare disease therapeutics. Pharmaceutical companies are finding greater incentive in supportive regulatory environments that offer market exclusivity and tax benefits for creating treatments for low-prevalence conditions, shifting the focus from purely surgical management to pharmacological prevention. According to the U.S. Food and Drug Administration's 'New Drug Therapy Approvals 2023' report from January 2024, 28 of the 55 novel drugs approved in 2023 were designated for rare diseases, indicating a sustained industry pivot toward addressing unmet needs in hereditary conditions. Furthermore, the urgency of developing these treatments is underscored by mortality data; the American Cancer Society projects that colorectal cancer will cause 53,010 deaths in the United States in 2024, driving the demand for more effective drugs to improve patient survival.

Market Challenge

The considerable economic strain linked to lifelong surveillance and complex surgical procedures serves as a major barrier to the growth of the Gardner Syndrome treatment sector. Patients with this hereditary condition need continuous medical management, including frequent endoscopic exams and major interventions like colectomy to lower cancer risks, which result in high direct medical costs that limit patient access to standard care. When individuals are unable to afford the necessary prophylactic regimen, adherence to treatment protocols drops, effectively reducing the volume of surgeries performed and the demand for pharmacological management options.

According to the American Cancer Society Cancer Action Network in 2024, roughly 47 percent of patients and survivors reported difficulty covering costs associated with cancer care, including screening and treatment expenses. This widespread financial toxicity suggests that a large segment of the potential patient population may delay or forgo critical monitoring and surgery due to economic pressures. Consequently, the market faces diminished revenue opportunities as financial constraints restrict the widespread adoption of essential therapeutic interventions.

Market Trends

The sector is witnessing a significant transition toward minimally invasive and robotic proctocolectomy, driven by the clinical need to reduce surgical trauma and preserve nerve function during prophylactic bowel removal. Robotic systems are increasingly preferred over open techniques due to their enhanced precision within the narrow pelvic cavity, which is essential for minimizing complications during restorative procedures like ileal pouch-anal anastomosis. This technological integration is rapidly redefining surgical standards for hereditary colorectal conditions; according to the 'Intuitive Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results' press release from January 2025, worldwide da Vinci procedures increased by approximately 17 percent in 2024 compared to the previous year, reflecting the expanding scale of robotic adoption in complex abdominal interventions.

At the same time, the introduction of gamma-secretase inhibitors marks a transformative step in managing desmoid tumors, a life-threatening extracolonic manifestation of Gardner Syndrome. This trend indicates a therapeutic shift from high-risk surgical resections, which often lead to recurrence, toward targeted pharmacological suppression of the Notch signaling pathway to induce tumor regression. The strong commercial uptake of these novel therapeutics highlights the urgent demand for effective non-surgical options; according to SpringWorks Therapeutics' 'Fourth Quarter and Full Year 2024 Financial Results' report from February 2025, the company recorded full-year 2024 U.S. net product revenue of $172.0 million for OGSIVEO (nirogacestat), validating the substantial market adoption of approved systemic therapies for this previously underserved patient segment.

Key Market Players

• Biochem Pharmaceuticals Industries Limited
• Zydus Lifesciences Limited
• Vernalis (R&D) Limited
• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Medimetriks Pharmaceuticals, Inc
• Johnson & Johnson Services, Inc.
• Akorn Operating Company LLC

Report Scope

In this report, the Global Gardner Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gardner Syndrome Treatment Market, By Cancer Type

• Dilated Cardiomyopathy
• Skeletal Myopathy
• Neutropenia
• Others

Gardner Syndrome Treatment Market, By Therapeutics Type

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• COX-2 Inhibitor

Gardner Syndrome Treatment Market, By End user

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Gardner Syndrome Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gardner Syndrome Treatment Market.

Available Customizations:

Global Gardner Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gardner Syndrome Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type (Dilated Cardiomyopathy, Skeletal Myopathy, Neutropenia, Others)
  • 5.2.2. By Therapeutics Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 Inhibitor)
  • 5.2.3. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Gardner Syndrome Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Therapeutics Type
  • 6.2.3. By End user
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gardner Syndrome Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Therapeutics Type
      • 6.3.1.2.3. By End user
  • 6.3.2. Canada Gardner Syndrome Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Therapeutics Type
      • 6.3.2.2.3. By End user
  • 6.3.3. Mexico Gardner Syndrome Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Therapeutics Type
      • 6.3.3.2.3. By End user

7. Europe Gardner Syndrome Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Therapeutics Type
  • 7.2.3. By End user
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gardner Syndrome Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Therapeutics Type
      • 7.3.1.2.3. By End user
  • 7.3.2. France Gardner Syndrome Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Therapeutics Type
      • 7.3.2.2.3. By End user
  • 7.3.3. United Kingdom Gardner Syndrome Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Therapeutics Type
      • 7.3.3.2.3. By End user
  • 7.3.4. Italy Gardner Syndrome Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Type
      • 7.3.4.2.2. By Therapeutics Type
      • 7.3.4.2.3. By End user
  • 7.3.5. Spain Gardner Syndrome Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Type
      • 7.3.5.2.2. By Therapeutics Type
      • 7.3.5.2.3. By End user

8. Asia Pacific Gardner Syndrome Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Therapeutics Type
  • 8.2.3. By End user
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gardner Syndrome Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Therapeutics Type
      • 8.3.1.2.3. By End user
  • 8.3.2. India Gardner Syndrome Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Therapeutics Type
      • 8.3.2.2.3. By End user
  • 8.3.3. Japan Gardner Syndrome Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Therapeutics Type
      • 8.3.3.2.3. By End user
  • 8.3.4. South Korea Gardner Syndrome Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Type
      • 8.3.4.2.2. By Therapeutics Type
      • 8.3.4.2.3. By End user
  • 8.3.5. Australia Gardner Syndrome Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Type
      • 8.3.5.2.2. By Therapeutics Type
      • 8.3.5.2.3. By End user

9. Middle East & Africa Gardner Syndrome Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Therapeutics Type
  • 9.2.3. By End user
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gardner Syndrome Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Therapeutics Type
      • 9.3.1.2.3. By End user
  • 9.3.2. UAE Gardner Syndrome Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Therapeutics Type
      • 9.3.2.2.3. By End user
  • 9.3.3. South Africa Gardner Syndrome Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Therapeutics Type
      • 9.3.3.2.3. By End user

10. South America Gardner Syndrome Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Type
  • 10.2.2. By Therapeutics Type
  • 10.2.3. By End user
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gardner Syndrome Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Type
      • 10.3.1.2.2. By Therapeutics Type
      • 10.3.1.2.3. By End user
  • 10.3.2. Colombia Gardner Syndrome Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Type
      • 10.3.2.2.2. By Therapeutics Type
      • 10.3.2.2.3. By End user
  • 10.3.3. Argentina Gardner Syndrome Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Type
      • 10.3.3.2.2. By Therapeutics Type
      • 10.3.3.2.3. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gardner Syndrome Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Biochem Pharmaceuticals Industries Limited
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Zydus Lifesciences Limited
• 15.3. Vernalis (R&D) Limited
• 15.4. Sun Pharmaceutical Industries Ltd.
• 15.5. Sanofi S.A.
• 15.6. Novartis AG
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Medimetriks Pharmaceuticals, Inc
• 15.9. Johnson & Johnson Services, Inc.
• 15.10. Akorn Operating Company LLC

16. Strategic Recommendations

17. About Us & Disclaimer